Andrew R. Boll bought HROW once, on May 14, 2026

Andrew R. Boll is the President, Chief Financial Officer, and Corporate Secretary of Harrow, Inc. (NASDAQ: HROW), a U.S. eyecare pharmaceutical company focused on developing and commercializing innovative ophthalmic prescription therapies.( One of Harrow’s founding employees, he has played a central role in the company’s evolution from its start-up phase through its NASDAQ listing, licensing and M&A activities, and current commercial stage.( In his executive roles, Boll oversees Harrow’s financial and administrative operations and is considered a key member of its leadership team.( He has also been involved in forming and creating related healthcare businesses, including Eton Pharmaceuticals, Surface Ophthalmics, Melt Pharmaceuticals, and ImprimisRx.(

Before joining Harrow, Boll worked from 2007 to 2011 at an investment company, where he managed fund accounting, financial analysis, and reporting, and was heavily involved in the financial operations of several public and private portfolio companies.( Earlier in his career, he held various accounting roles at Welsh Companies, LLC, a commercial real estate firm, its fund, and subsidiaries.( Boll is a CFA® charterholder and a Certified Management Accountant, and he earned his Bachelor of Science degree in Corporate and Public Finance, graduating summa cum laude.( He remains an active corporate insider at Harrow, recently purchasing additional shares of the company’s common stock in his capacity as President and CFO.(

Written by Perplexity from public sources.